FDA compounder NDC directory
Browse every current FDA compounder source row, including records that do not contain a usable NDC.
Compounder NDC directory#
Every current compounder source row is browsable, including records whose FDA source did not provide a usable product, package, or lookup NDC. Browse the unified current auxiliary catalog. · Browse the complete captured source and snapshot history.
| Establishment | FEI | Product NDC | Package NDC | Brand | Nonproprietary name | Active ingredients | Period | Normalization | Source date |
|---|---|---|---|---|---|---|---|---|---|
| Hybrid Pharma | 079665742 | 26436-5137 | 26436-5137-5 | Papaverine Hydrochloride; Alprostadil; Phentolamine Mesylate | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2026-1 | valid | 2026-10-06 | |
| Hybrid Pharma | 26436-5137 | 26436-5137-5 | Trimix 20/30/2 | Trimix 20/30/2 | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2026-1 | valid | 2026-09-18 | |
| Hybrid Pharma | 079665742 | 26436-5137 | 26436-5137-5 | Papaverine Hydrochloride; Alprostadil; Phentolamine Mesylate | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2025-2 | valid | 2026-10-06 | |
| Hybrid Pharma | 26436-5137 | 26436-5137-5 | Trimix 20/30/2 | Trimix 20/30/2 | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2025-2 | valid | 2026-09-18 | |
| Hybrid Pharma | 079665742 | 26436-5137 | 26436-5137-5 | Papaverine Hydrochloride; Alprostadil; Phentolamine Mesylate | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2025-1 | valid | 2026-10-06 | |
| Hybrid Pharma | 26436-5137 | 26436-5137-5 | Trimix 20/30/2 | Trimix 20/30/2 | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2025-1 | valid | 2026-09-18 | |
| Hybrid Pharma | 079665742 | 26436-5137 | 26436-5137-5 | Papaverine Hydrochloride; Alprostadil; Phentolamine Mesylate | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2024-2 | valid | 2026-10-06 | |
| Hybrid Pharma | 26436-5137 | 26436-5137-5 | Trimix 20/30/2 | Trimix 20/30/2 | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2024-2 | valid | 2026-09-18 | |
| Hybrid Pharma | 079665742 | 26436-5137 | 26436-5137-5 | Papaverine Hydrochloride; Alprostadil; Phentolamine Mesylate | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2024-1 | valid | 2026-10-06 | |
| Hybrid Pharma | 079665742 | 26436-5137 | 26436-5137-5 | Papaverine Hydrochloride; Alprostadil; Phentolamine Mesylate | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2023-2 | valid | 2026-10-06 | |
| Hybrid Pharma | 079665742 | 26436-5137 | 26436-5137-5 | Papaverine Hydrochloride; Alprostadil; Phentolamine Mesylate | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2023-1 | valid | 2026-10-06 | |
| Hybrid Pharma | 079665742 | 26436-5137 | 26436-5137-5 | Papaverine Hydrochloride; Alprostadil; Phentolamine Mesylate | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2021-2 | valid | 2026-10-06 | |
| Hybrid Pharma | 079665742 | 26436-5137 | 26436-5137-5 | Papaverine Hydrochloride; Alprostadil; Phentolamine Mesylate | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2020-2 | valid | 2026-10-06 | |
| Hybrid Pharma | 079665742 | 26436-5137 | 26436-5137-5 | Papaverine Hydrochloride; Alprostadil; Phentolamine Mesylate | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2020-1 | valid | 2026-10-06 | |
| Hybrid Pharma | 079665742 | 26436-5137 | 26436-5137-1 | Papaverine Hydrochloride; Alprostadil; Phentolamine Mesylate | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2019-2 | valid | 2026-10-06 | |
| Hybrid Pharma | 079665742 | 26436-5137 | 26436-5137-5 | Papaverine Hydrochloride; Alprostadil; Phentolamine Mesylate | 30 mg/1 mL; 20 ug/1 mL; 2 mg/1 mL | 2019-2 | valid | 2026-10-06 |